FindTrial
Sign In

To Determine the Safety and Anti Aging Benefits of De Age Total Longevity Supplement in Healthy Adults

A Prospective Open Label Clinical Study to Assess the Safety and Anti Aging Efficacy of De-Age Total Longevity Supplement via NAD Level Modulation in Healthy Adult male and female participants - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109231
Enrollment
30
Registered
2026-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: De-Age Total Rise Restore formulation: one Rise sachet in 200 ml water before breakfast and one Restore sachet in 200 ml water before bedtime daily for 90 days Control Intervention1: NA

Sponsors

Herbs Nutriproducts Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy male and female participants in the age group of 40 65 years both age inclusive Participant is having valid proof of identity and age Participant having BMI 18 5 35 0 kg m Willing and able to provide written informed consent Ability to consume product and comply with study procedures Willing to maintain current lifestyle habits during study participation Females of childbearing potential must use reliable contraception Participant willing to perform UPT for females only

Exclusion criteria

Exclusion criteria: Participant with any Significant acute or chronic medical conditions diabetes cardiovascular disease hepatic or renal impairment Participant Using any anti aging supplements oral or topical within 30 days Participant is pregnant lactating or planning pregnancy during study period Participant with Current smoking or alcohol abuse 14 units week Participant with Known allergies or hypersensitivity to any study ingredients Participant who has participated in other clinical trials within 30 days Participant having Abnormal screening laboratory values deemed clinically significant

Design outcomes

Primary

MeasureTime frame
Mean change from baseline to Day 90 in whole blood NAD levels as the core molecular biomarker of cellular ageing and longevity Mean change from baseline to Day 90 in skin hydration Corneometer and skin elasticity Cutometer as objective markers of cutaneous ageingTimepoint: Visit 01 Day 0 Baseline Visit 02 Day 30 Visit 03 Day 60 Visit 04 Day 90—

Secondary

MeasureTime frame
Biological Age & Longevity Biomarkers Physical Function & Musculoskeletal Health Dermat Rated Outcomes Patient Reported Outcomes Safety Endpoints Compliance EndpointTimepoint: Visit 01 Day 0 Baseline Visit 02 Day 30 Visit 03 Day 60 Visit 04 Day 90—

Countries

India

Contacts

Public ContactDr Sanjay Mishra

Auriga Research Private Limited

sanmishra75@gmail.com08527569065

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026